<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2304-0106</journal-id>
<journal-title><![CDATA[Anales de la Academia de Ciencias de Cuba]]></journal-title>
<abbrev-journal-title><![CDATA[Anales de la ACC]]></abbrev-journal-title>
<issn>2304-0106</issn>
<publisher>
<publisher-name><![CDATA[Academia de Ciencias de Cuba]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2304-01062023000100019</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[SOBERANA®Plus: refuerzo seguro y eficaz de la inmunidad natural pre-existente contra SARS-CoV-2]]></article-title>
<article-title xml:lang="en"><![CDATA[SOBERANA®Plus: safe and efficient booster of the preexistingnatural immunity against SARS-CoV-2]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Verez Bencomo]]></surname>
<given-names><![CDATA[Vicente]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ochoa Azze]]></surname>
<given-names><![CDATA[Rolando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Rivera]]></surname>
<given-names><![CDATA[Dagmar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Climent Ruiz]]></surname>
<given-names><![CDATA[Yanet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valdés Balbín]]></surname>
<given-names><![CDATA[Yury]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chang Monteagudo]]></surname>
<given-names><![CDATA[Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valenzuela Silva]]></surname>
<given-names><![CDATA[Carmen María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Macías Abraham]]></surname>
<given-names><![CDATA[Consuelo Milagro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Ramírez]]></surname>
<given-names><![CDATA[Belinda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Noda]]></surname>
<given-names><![CDATA[Laura Marta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Perez Nicado]]></surname>
<given-names><![CDATA[Rocmira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández García]]></surname>
<given-names><![CDATA[Tays]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Orosa Vázquez]]></surname>
<given-names><![CDATA[Ivette]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Hernández]]></surname>
<given-names><![CDATA[Marianniz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández Medina]]></surname>
<given-names><![CDATA[Olivia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valdés Zayas]]></surname>
<given-names><![CDATA[Anet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García García]]></surname>
<given-names><![CDATA[María de los Ángeles]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jerez Barceló]]></surname>
<given-names><![CDATA[Yanet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Triana Marrero]]></surname>
<given-names><![CDATA[Yenisey]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz Villegas]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Prieto]]></surname>
<given-names><![CDATA[Luis Dairon]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Puga Gómez]]></surname>
<given-names><![CDATA[Rinaldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guerra Chaviano]]></surname>
<given-names><![CDATA[Pedro Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zúñiga Rosales]]></surname>
<given-names><![CDATA[Yaíma]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marcheco Teruel]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Acosta]]></surname>
<given-names><![CDATA[Mireida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Noa Romero]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Enríquez Puertas]]></surname>
<given-names><![CDATA[Juliet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ontivero Pino]]></surname>
<given-names><![CDATA[Ivis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Camaraza Soler]]></surname>
<given-names><![CDATA[María Amalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Porto González]]></surname>
<given-names><![CDATA[Delia Esther]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera Martínez]]></surname>
<given-names><![CDATA[Luis Saturnino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A11"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Finlay de Vacunas  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Hematología e Inmunología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto de Cibernética, Matemática y Física  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Centro de Inmunología Molecular  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Clínica Central Cira García  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Centro Nacional Coordinador de Ensayos Clínicos  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Centro Nacional de Genética Médica  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Centro de Investigaciones Científicas de la Defensa Civil  ]]></institution>
<addr-line><![CDATA[ Mayabeque]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Ministerio de Salud Pública  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="A10">
<institution><![CDATA[,BioCubaFarma  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="A11">
<institution><![CDATA[,Academia de Ciencias de Cuba  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<volume>13</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2304-01062023000100019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2304-01062023000100019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2304-01062023000100019&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La vacuna SOBERANA®Plus se evaluó en convalecientes de COVID-19 ante la emergencia de nuevas variantes del SARS-CoV-2. SOBERANA®Plus se basa en el dímero de la proteína recombinante del dominio de unión al receptor (RBD) con secuencia 319-354.  Métodos: Se ejecutaron 2 estudios clínicos, en los que se evaluó una dosis de la vacuna. En el ensayo Fase I abierto en 30 convalecientes de COVID-19 con cuadro clínico asintomático y leve, en edades entre 22 años hasta 57 años, se evaluó su seguridad, reactogenicidad e inmunogenicidad, mediante ELISA anti-RBD, la prueba de inhibición in vitro RBD:hACE2, la de neutralización viral y la evaluación de células T efectoras. Inscrito en el Registro Público Cubano de Ensayos Clínicos, WHO-ICTRP: https://rpcec.sld.cu/en/trials/RPCEC00000349-Sp. El estudio Fase II, controlado, aleatorizado y con grupo placebo, en 450 convalecientes de COVID-19 asintomático, leve o moderado, entre 19 años hasta 78 años de edad. Se evaluó la reactogenicidad e inmunogenicidad humoral. WHO-ICTRP: https://rpcec.sld.cu/en/trials/RPCEC00000366-Sp.  Resultados y Discusión: En ambos estudios no se reportaron eventos adversos graves. Predominaron los leves, el más común, dolor local. La vacuna estimuló un incremento mayor que 21 veces de los anticuerpos IgG anti-RBD 28 días después de la vacunación en el ensayo Fase I, y mayor que 31 veces en el Fase II. La mediana de los títulos de anticuerpos inhibidores en ambas fases fue de 94,0 %. Se detectó un aumento significativo de los títulos de neutralización viral contra las variantes D614G, alfa, beta y delta, y de las células T específicas que producen IFN-&#947; y TNF-&#945;. Conclusiones, se demostró que SOBERANA®Plus tiene un excelente perfil de seguridad y que una sola dosis es capaz de reforzar eficazmente la inmunidad natural preexistente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  SOBERANA®Plus vaccine was evaluated in COVID-19 convalescents in the face of the emergence of new SARS-CoV-2 variants. SOBERANA®Plus is based on the recombinant receptor binding domain (RBD) protein dimer with sequence 319-354.  Methods:  Two clinical studies were executed, in which one dose of the vaccine was evaluated. In the open-label Phase I clinical trial, in 30 COVID-19 convalescents with asymptomatic and mild clinical presentation, aged 22 to 57 years, safety, reactogenicity and immunogenicity were evaluated, by means of anti-RBD ELISA, in vitro RBD:hACE2 inhibition test, viral neutralization test and evaluation of effector T cells. Registered in the Cuban Public Registry of Clinical Trials, WHO-ICTRP: https://rpcec.sld.cu/en/trials/RPCEC00000349-Sp. The randomized and placebo-controlled Phase II study, in 450 COVID-19 convalescents, asymptomatic, mild or moderate, between 19 and 78 years of age. Reactogenicity and humoral immunogenicity were evaluated. WHO-ICTRP: https://rpcec.sld.cu/en/trials/RPCEC00000366-Sp.  Results and Discussion:  No serious adverse events were reported in both studies. Mild events predominated, being the most common, the local pain. The vaccine stimulated an increase of &gt;21-fold in the anti-RBD IgG antibodies 28 days after vaccination in the Phase I trial, and &gt;31-fold in the Phase II trial. Median of inhibitory antibody titers in both phases were 94.0%. A significant increase in viral neutralizing titers against D614G, alpha, beta and delta variants, and specific IFN-&#947;- and TNF-&#945;-producing T cells was detected. Conclusions, SOBERANA®Plus has demonstrated an excellent safety profile and a single dose was able to effectively boost pre-existing natural immunity.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Infección por SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[vacunas contra la COVID-19]]></kwd>
<kwd lng="es"><![CDATA[seguridad]]></kwd>
<kwd lng="es"><![CDATA[inmunogenicidad]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2 Infection]]></kwd>
<kwd lng="en"><![CDATA[COVID-19 Vaccines]]></kwd>
<kwd lng="en"><![CDATA[safety]]></kwd>
<kwd lng="en"><![CDATA[immunogenicity]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi-Lee]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wheatley]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Kent]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[DeKosky]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies]]></article-title>
<source><![CDATA[Nature Microbiology]]></source>
<year>2020</year>
<volume>5</volume>
<page-range>1185-91</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arvin]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Fink]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Cathcart]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Spreafico]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Havenar-Daughton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A perspective on potential antibody-dependent enhancement of SARS-CoV-2]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2020</year>
<volume>584</volume>
<page-range>353-63</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Pérez]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Sandoval]]></surname>
<given-names><![CDATA[MLP]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Altamirano]]></surname>
<given-names><![CDATA[M.S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Participantes de la respuesta inmunológica ante la infección por SARS-CoV-2]]></article-title>
<source><![CDATA[Alerg. Asma Inmunol. Pediatr]]></source>
<year>2020</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-15</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeyanathan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Afkhami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Smaill]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Lichty]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Zh]]></surname>
<given-names><![CDATA[Xing]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunological considerations for COVID-19 vaccine strategies]]></article-title>
<source><![CDATA[Nat. Rev. Immunol]]></source>
<year>2020</year>
<volume>20</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>615-32</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Mertens]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Crider]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pokpongkiat]]></surname>
<given-names><![CDATA[NN]]></given-names>
</name>
<name>
<surname><![CDATA[Djajadi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Substantial underestimation of SARS-CoV-2 infection in the United States]]></article-title>
<source><![CDATA[Natute Communications]]></source>
<year>2020</year>
<volume>11</volume>
<numero>4507</numero>
<issue>4507</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Protocolo de actuación nacional para la COVID-19]]></source>
<year>2020</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishiura]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Miyama]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[S.M]]></given-names>
</name>
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)]]></article-title>
<source><![CDATA[Int. J. Infect. Dis]]></source>
<year>2020</year>
<volume>94</volume>
<page-range>154-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kuchipudi]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Eagar]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Yi]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma]]></article-title>
<source><![CDATA[bioRxiv preprint]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PhJM]]></surname>
<given-names><![CDATA[Brouwer]]></given-names>
</name>
<name>
<surname><![CDATA[Caniels]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[van der Straten]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Snitselaar]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Aldon]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bangaru]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability]]></article-title>
<source><![CDATA[Science]]></source>
<year>2020</year>
<volume>369</volume>
<numero>6504</numero>
<issue>6504</issue>
<page-range>643-50</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hotez]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Corry]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Strych]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Bottazzi]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 vaccines: neutralizing antibodies and the alum advantage]]></article-title>
<source><![CDATA[Nat Rev Immunol]]></source>
<year>2020</year>
<volume>20</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>399-400</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Shen]]></given-names>
</name>
<name>
<surname><![CDATA[Zh]]></surname>
<given-names><![CDATA[Wang]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of 5 critically ill patients with COVID-19 with convalescent plasma]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>323</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1582-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2020</year>
<volume>586</volume>
<numero>7830</numero>
<issue>7830</issue>
<page-range>572-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alturki]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Alturki-Sawsan]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Connors]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cusimano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kutzler]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Izmirly]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Haddad]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2020 Pandemic: Current SARS-CoV-2Vaccine Development]]></article-title>
<source><![CDATA[Front. Immunol]]></source>
<year>2020</year>
<volume>11</volume>
<numero>1880</numero>
<issue>1880</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang-Monteagudo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa-Azze]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Climent-Ruiz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Macías-Abraham]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Noda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela-Silva]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial]]></article-title>
<source><![CDATA[The Lancet Regional Health-Americas]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa-Azze]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chang-Monteagudo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Climent-Ruiz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Macías-Abraham]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela-Silva]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[de los Ángeles García-García]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial]]></article-title>
<source><![CDATA[The Lancet Respiratory Medicine]]></source>
<year>2022</year>
<volume>10</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>785-95</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>Brighton Collaboration</collab>
<source><![CDATA[Case definitions. Basel: BC]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>US Department of Health and Human Services</collab>
<source><![CDATA[Common Terminology Criteria for Adverse Events (CTCAE)]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[HHS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Causality Assessment of an Adverse Event Following Immunization (AEFI)]]></source>
<year>2019</year>
<edition>2nd</edition>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plikaytis]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Carlone]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<source><![CDATA[Program ELISA for Windows User´s Manual]]></source>
<year>2005</year>
<publisher-loc><![CDATA[Atlanta, GA ]]></publisher-loc>
<publisher-name><![CDATA[Centers for Disease Control and Prevention]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Chia]]></surname>
<given-names><![CDATA[WN]]></given-names>
</name>
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[MIC]]></given-names>
</name>
<name>
<surname><![CDATA[Tiu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction]]></article-title>
<source><![CDATA[Nat. Biotechnol]]></source>
<year>2020</year>
<volume>38</volume>
<page-range>1073-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manenti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maggetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Casa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martinuzzi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Torelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Trombetta]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples]]></article-title>
<source><![CDATA[J. Med. Virol]]></source>
<year>2020</year>
<volume>92</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2096-104</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keech]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine]]></article-title>
<source><![CDATA[NEJM]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
